Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Lisy, Wang"'
Autor:
Gustavo Citera, Rakesh Jain, Fedra Irazoque, Hugo Madariaga, David Gruben, Lisy Wang, Lori Stockert, Karina Santana, Abbas Ebrahim, Dario Ponce de Leon
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 35-50 (2023)
Abstract Introduction The aim of our work is to assess the prevalence of probable major depressive disorder and/or probable generalized anxiety disorder (pMDD/pGAD) in patients with moderate to severe rheumatoid arthritis (RA), and to evaluate the ef
Externí odkaz:
https://doaj.org/article/10f6808001604d89b3ef4c2752f7a120
Autor:
Adrian Ciurea, Oliver Distler, Kenneth Kwok, Hyejin Jo, Lisy Wang, Tim Killeen, Caroline Ospelt, Mojca Frank Bertoncelj
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-11 (2023)
Abstract Background Rheumatoid arthritis (RA) has a variable impact on different synovial joints, with inflammation being more commonly observed in some joints than others. Emerging evidence suggests that the anatomical variation in pathophysiology c
Externí odkaz:
https://doaj.org/article/9479b52939a04c16b0a79b727ac1a436
Autor:
David Cella, William R. Lenderking, Peter Chongpinitchai, Andrew G. Bushmakin, Oluwaseyi Dina, Lisy Wang, Joseph C. Cappelleri, Victoria Navarro-Compán
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 6, Iss 1, Pp 1-10 (2022)
Plain English summary Ankylosing spondylitis (AS) is a disease that causes pain and stiffness in the spine. AS is a chronic disease. Most people with AS experience fatigue (a feeling of being very tired or exhausted). People with more severe AS tend
Externí odkaz:
https://doaj.org/article/6e9e80fde3c949509ec55f332601f2dc
Autor:
Maxime Dougados, Peter C Taylor, Clifton O Bingham, Lisy Wang, Lara Fallon, Satrajit Roychoudhury, Yves Brault, Meriem Kessouri
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objective Post hoc analysis of pooled data from nine randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) on residual pain in patients
Externí odkaz:
https://doaj.org/article/718c987b34ca40a3929222a0f56b3617
Autor:
Filip van den Bosch, Vibeke Strand, Cunshan Wang, Joseph C Cappelleri, Joseph Wu, Marina Magrey, James Cheng-Chung Wei, Victoria Navarro-Compán, Lisy Wang, Lara Fallon, Dona Fleishaker, Oluwaseyi Dina
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/bb08d9b2f36945409ceb39e02e7a8c8a
Autor:
Janet E. Pope, Edward Keystone, Shahin Jamal, Lisy Wang, Lara Fallon, John Woolcott, Irina Lazariciu, Douglass Chapman, Boulos Haraoui
Publikováno v:
ACR Open Rheumatology, Vol 1, Iss 2, Pp 73-82 (2019)
ABSTRACT Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis evaluated tofacitinib persistence in patients with RA in long‐term extension (LTE) studies up to 9.5 years. Meth
Externí odkaz:
https://doaj.org/article/10a7f160ef4a4bb2979891238ac01951
Autor:
Jürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R. Curtis, Joel Silverfield, Ketti Terry, Koshika Soma, Chris Mojcik, Ryan DeMasi, Sander Strengholt, Kenneth Kwok, Irina Lazariciu, Lisy Wang, Stanley Cohen
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-18 (2019)
Abstract Background Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA). Method
Externí odkaz:
https://doaj.org/article/cbd75ed150f44a9ea233626add2ba876
Autor:
Peter Nash, Yoshiya Tanaka, Kevin L Winthrop, Eun Bong Lee, Xavier Mariette, Jeffrey R Curtis, Kenneth Kwok, Connie Chen, Pinaki Biswas, Lisy Wang, Christina Charles-Schoeman, Ann Madsen, Stanley B Cohen, Andrea Shapiro, Jürgen Wollenhaupt
Publikováno v:
RMD Open, Vol 6, Iss 3 (2020)
Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term e
Externí odkaz:
https://doaj.org/article/06d315c88fb8416d89479fa698afb87f
Autor:
Zhan-Guo Li, Yi Liu, Hu-Ji Xu, Zhi-Wei Chen, Chun-De Bao, Jie-Ruo Gu, Dong-Bao Zhao, Yuan An, Lie-Ju Hwang, Lisy Wang, Joel Kremer, Qi-Zhe Wu
Publikováno v:
Chinese Medical Journal, Vol 131, Iss 22, Pp 2683-2692 (2018)
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This study assessed the efficacy and safety of tofacitinib in Chinese patients with RA enrolled in Phase 3 and long-term extension (LTE) studies
Externí odkaz:
https://doaj.org/article/38277dc7cf034a43a255067a86bdad8b
Autor:
Ruediger B. Mueller, Hendrik Schulze-Koops, Daniel E. Furst, Stanley B. Cohen, Kenneth Kwok, Lisy Wang, Tim Killeen, Johannes von Kempis
Publikováno v:
Clinical Rheumatology. 41:1045-1055
Introduction/objectives We assess the impact of switching versus staying on the same tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis (RA). Methods ORAL Sequel was an open-label, long-term extension study of patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cde326cd84546180ea96bdb8fef278e
https://doi.org/10.1007/s10067-021-05908-z
https://doi.org/10.1007/s10067-021-05908-z